<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>482</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15451471</PubmedId>
            <Abstract>To assess specific cytotoxic T lymphocytes (CTLs) against Severe acute respiratory syndrome (SARS)-coronavirus, a modified DimerX flow cytometry assay was performed with peripheral blood mononuclear cell (PBMC) from HLA-A2+ SARS-recovered donors at different time points post disease. CD8+DimerX-S1203+ CTLs were detected in the PBMC from these donors up to 3 months after recovery. The percentages of CD8+DimerX-S1203+ cells paralleled the numbers of interferon-gamma-positive spots in an ELISPOT assay using the same antigenic peptide. In conclusion, DimerX-based flow cytometry staining may prove to be a real-time method to screen for CTL directed at epitopes from a newly identified virus.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>151-4</ArticlePages>
            <ArticleTitle>Detecting specific cytotoxic T lymphocytes against SARS-coronavirus with DimerX HLA-A2:Ig fusion protein.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Yue-Dan</ForeName>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Wei Feng</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Immunology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100083, China. wangyuedan@hotmail.com.</Affiliations>
            <ArticleChemicalList>Epitopes, T-Lymphocyte;HLA-A2 Antigen;Immunoglobulins;Viral Fusion Proteins;Iothalamic Acid;iocarmate meglumine;Meglumine;Interferon-gamma</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Epitopes, T-Lymphocyte(immunology); Flow Cytometry; HLA-A2 Antigen(immunology); Humans; Immunoglobulins(immunology); Interferon-gamma(immunology); Iothalamic Acid(analogs &amp; derivatives); Meglumine; SARS Virus(immunology); Severe Acute Respiratory Syndrome(immunology); T-Lymphocytes, Cytotoxic(immunology); Viral Fusion Proteins</ArticleMeshHeadingsList>
            <Journal>
                <Volume>113</Volume>
                <Issue>2</Issue>
                <Title>Clinical immunology (Orlando, Fla.)</Title>
                <Issn>1521-6616</Issn>
                <MedlineTa>Clin Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>S1203</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FIAGLIAIV</LinearSequence>
                        <StartingPosition>1202</StartingPosition>
                        <EndingPosition>1210</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P59594.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>694009</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 151</LocationOfData>
                <EpitopeId>16156</EpitopeId>
                <ReferenceStartingPosition>1203</ReferenceStartingPosition>
                <ReferenceEndingPosition>1211</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1A</LocationOfData>
                        <TCellId>2943</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Sex>F</Sex>
                                <Age>20-23 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>S1203</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FIAGLIAIV</LinearSequence>
                                        <StartingPosition>1202</StartingPosition>
                                        <EndingPosition>1210</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P59594.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>694009</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>PBMC from HLA-A2 -negative SARS-recovered donors and healthy HLA-A2-positive donors showed no response in the assay.  No response was found to a negative control peptide derived from the homologous sequence in HcoV-229e (H1121 [ISVVLIFVV]).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1B</LocationOfData>
                        <TCellId>2964</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Sex>F</Sex>
                                <Age>20-23 years</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:2945</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>694009</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>SARS coronavirus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>S1203</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FIAGLIAIV</LinearSequence>
                                        <StartingPosition>1202</StartingPosition>
                                        <EndingPosition>1210</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P59594.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>694009</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>DimerX-based flow cytometry staining was used to screen PBMC from SARS donors.  PBMC from HLA-A2 -negative SARS-recovered donors and healthy HLA-A2-positive donors showed no response in the assay.  No response was found to a negative control peptide derived from the homologous sequence in HcoV-229e (H1121 [ISVVLIFVV]).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

